

In the specification:

On page 18, lines 8-11, please amend the paragraph as follows. A marked up version of the amendment is attached hereto as **Exhibit A**.

B2

--Plasmid pHu-IFN- α 001 is deposited with the American Type Culture Collection (ATCC) at 10801 University Boulevard, Manassas, VA 20110-2209; Accession No. 69640; Deposit date June 7, 1994; and designated as plasmid pHu-IFN- α 001 (E. coli DH5 α pHu-IFN- α 001 as the host vector system).--

In the Claims

Please amend the claims under the provisions of 37 C.F.R. 1.121(c) as follows. A marked up version of the claim as amended is attached hereto as **Exhibit B**.

B3

--18. (2X Amended) A purified or recombinantly produced polypeptide comprising an amino acid sequence of human interleukin-2 encoded by a gene from a diseased cell, which amino acid sequence is a modification of an amino acid sequence of a normal human interleukin-2, wherein the interleukin-2 gene from the diseased cell hybridizes under stringent wash conditions to a normal human interleukin-2 gene.--

B4

--19. (Amended) The purified or recombinantly produced polypeptide of claim 18, wherein the diseased cell is obtainable from a leukemic leukocyte.--

--20. (Amended) The purified or recombinantly produced polypeptide of claim 18, wherein the diseased cell is obtainable from human malignancies.--

B5

--37. (Amended) The polypeptide of claim 18, which polypeptide exhibits either antiviral activity, growth inhibition activity or immunosuppressive activity.--

--38. (Amended) The polypeptide of claim 18, which polypeptide is purified to homogeneity.--